原癌基因酪氨酸蛋白激酶Src
印戒细胞
转移
医学
癌症
癌变
印戒细胞癌
癌症研究
微卫星不稳定性
胃
癌
内科学
PI3K/AKT/mTOR通路
肿瘤科
病理
腺癌
生物
细胞凋亡
基因
受体
微卫星
等位基因
生物化学
作者
Kuo‐Hung Huang,Ming‐Huang Chen,Wen-Liang Fang,Chien-Hsing Lin,Yee Chao,Su-Shun Lo,Anna Fen–Yau Li,Chew-Wun Wu,Yi‐Ming Shyr
出处
期刊:Cancers
[Multidisciplinary Digital Publishing Institute]
日期:2020-08-17
卷期号:12 (8): 2318-2318
被引量:33
标识
DOI:10.3390/cancers12082318
摘要
Signet-ring cell carcinoma (SRC) in advanced gastric cancer (GC) is often associated with more invasiveness and a worse prognosis than other cell types. The genetic alterations associated with gastric carcinogenesis in SRC are still unclear. In this study, 441 GC patients receiving curative surgery for GC between 2005 and 2013 were enrolled. The clinicopathological characteristics and genetic alterations of GC patients with and without SRC were compared. Among the 441 GC patients, 181 had SRC. For early GC, patients with SRC had more tumors located in the middle and lower stomach, more infiltrating tumors and better overall survival (OS) rates than those without SRC. For advanced GC, patients with SRC had more scirrhous type tumors, more PIK3CA amplifications, fewer microsatellite instability-high (MSI-H) tumors, more peritoneal recurrences and worse 5-year OS rates than those without SRC. For advanced GC with SRC, patients with peritoneal recurrence tended to have PD-L1 expression. For advanced GC without SRC, patients with liver metastasis tended to have PD-L1 expression, PI3K/AKT pathway mutations, TP53 mutations and MSI-H tumors. For advanced GC, PD-L1 expression was associated with peritoneal recurrence in SRC tumors, while non-SRC tumors with liver metastasis were likely to have PI3K/AKT pathway mutations, TP53 mutations and PD-L1 expression; immunotherapy and targeted therapy may be beneficial for these patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI